Perceptions and acceptance of COVID-19 vaccine among pregnant and lactating women

in Singapore: A cross-sectional study

Dr Pooja A Jayagobi^{*1,2,3,4}, Chengsi Ong^{*1}, Yeo Kee Thai^{1,2,3,5}, Caleb CW Lim¹, Seet Meei

Jiun¹, Kwek Lee Koon¹, Ku Chee Wai^{1,2}, Jerry KY Chan^{1,2}, Manisha Mathur ** 1,2,3,4, Chua

Mei Chien**1,2,3,4

*Both authors contributed equally as first authors of this manuscript.

** Both authors contributed equally as senior authors in reviewing this manuscript

¹KK Women's and Children's Hospital

²Duke-NUS Medical School

³Lee Kong Chian School of Medicine

⁴NUS Yong Loo Lin School of Medicine

⁵Translational Immunology Institute

Abstract

Introduction

Vaccination is critical in controlling the coronavirus disease 19 (COVID-19) pandemic.

However, vaccine perception and acceptance among pregnant and lactating women is

unknown in Singapore. We aimed to determine the acceptance of COVID-19 vaccination

among these two groups of women in Singapore, and factors associated with vaccine

acceptance.

Methods

We conducted an anonymous, online survey on the perception and acceptance of the COVID-

19 vaccine in pregnant and lactating women at a tertiary hospital in Singapore from 1st March

to 31st May 2021. Information on demographics and knowledge were collected, and these

factors were assessed for their relationship with vaccine acceptance.

Results

A total of 201 pregnant and 207 lactating women participated. Vaccine acceptance rates in

pregnant and lactating women were 30.3% and 16.9% respectively. Pregnant women who

were unsure or unwilling to take the vaccine cited concerns about safety of the vaccine during

pregnancy (92.9%), while lactating women were concerned about potential long-term

negative effects on the breastfeeding child (75.6%). Other factors significantly associated

with vaccine acceptance included a lower monthly household income or education level,

appropriate knowledge regarding vaccine mechanism and higher perceived maternal risk of

COVID-19. Most pregnant (70.0%) and lactating women (83.7%) were willing to take the

vaccine only when more safety data during pregnancy and breastfeeding were available.

Conclusions

COVID-19 vaccine acceptance was low among pregnant and lactating women in Singapore.

Addressing safety concerns when more data is available and education on mechanism of

vaccine action will likely improve acceptance among these women.

Introduction

In this current coronavirus disease 2019 (COVID-19) pandemic, vaccination remains a critical strategy to curbing infections and reducing disease severity. Current approved COVID-19 vaccines in Singapore (Pfizer-BioNtech and the Moderna COVID-19 mRNA vaccines) have been found to be safe and efficacious in preventing severe disease. As these initial vaccine trials did not include pregnant and lactating women, Singapore's Ministry of Health (MOH) initially cautioned against vaccination in pregnant women, and recommended lactating women to stop breastfeeding for 5 to 7 days following vaccination. Here were in contrast to recommendations from the Society for Maternal-Fetal Medicine (SMFM) and American College of Obstetricians and Gynecologists (ACOG) that have maintained that the vaccine should be offered to pregnant and lactating women based on their risk, and that the mRNA-based vaccines are thought to pose a low risk to the fetus as the mRNA is expected to degrade in circulation. The World Health Organization and the Academy of Breastfeeding Medicine recommend that lactating women should continue to breastfeed post vaccination as it is unlikely for mRNA-based vaccines to be transmitted via breast milk. The property of the proper

With the emerging local and international clinical reports on the safety and efficacy of mRNA-based COVID-19 vaccines, MOH, Singapore approved the use of these vaccines for pregnant women and recommended lactating women to continue breastfeeding after vaccination on 31 May 2021. Pregnant women are a vulnerable group in this pandemic, with an increased risk for severe disease and adverse outcomes if infected, including preterm birth, venous thromboembolism, severe respiratory complications requiring invasive ventilation. (9
12) Lactating mothers could also potentially infect the infant postnatally via droplet infection. (13,14) Despite the benefits of vaccination to prevent maternal and fetal complications, studies have demonstrated varying rates of vaccine acceptance in pregnant and lactating

women. (15,16) Reported factors affecting acceptance included confidence in the safety and efficacy of the vaccine, level of trust in public health agencies, perceived lack of research and

fear of harming the fetus. (15,16)

We undertook this survey to evaluate the perceptions and factors affecting acceptance of the COVID-19 vaccine among pregnant and lactating women in a tertiary care centre in Singapore. We propose that the results will inform healthcare providers and policymakers on reasons for vaccine refusal, which can help develop strategies to improve vaccine uptake in

Methods

these groups of women.

This was a cross-sectional, web-based survey conducted at a tertiary maternal and child hospital in Singapore. Pregnant and lactating women over 21 years of age, attending outpatient clinics or admitted to the hospital were invited to participate in an anonymous, online survey from 1st March to 31st May 2021. Participation was voluntary and no incentive was offered for participation. No personally identifiable data was collected. The survey was advertised at outpatient clinics, inpatient nurseries and obstetric wards, and among the hospital's healthcare workers via posters and flyers. Ethics approval was obtained from the Singhealth Institutional Review Board (CIRB Ref No.: 2020/2648) with a waiver for informed consent.

Separate surveys were designed for lactating mothers and for pregnant women using input from other published studies and healthcare professionals. The surveys were developed and administered in English, and consisted of questions on demographics, vaccine acceptance, general health status, COVID-19 experience, knowledge regarding the COVID-19 vaccine, and participant perceptions and concerns regarding the COVID-19 vaccine. The full survey consisted of 22 questions for pregnant women and 28 questions for lactating mothers.

Responses to all the questions were in multiple-choice format. Perceptions of COVID-19

vaccine were rated on a 5-point Likert Scale.

The surveys were hosted on an online self-service form builder which stores responses in an

encrypted format and accessible only to the creator via a special code (Form.gov.sg, GovTech,

Singapore). Entry into the survey was via a QR code printed on the invitation flyer given to

the respondents. All the questions were mandatory and displayed in running order on the

respondent's screen. Respondents were prompted to complete the outstanding questions

before submitting the form, and were unable to save responses or change their answers after

submission.

All submitted surveys were included in the analysis of this study. Vaccine acceptance was

defined as a response of "strongly agree" or "agree" to take the vaccine if offered, while

vaccine non-acceptance was defined as a response of "unsure", "disagree" or "strongly

disagree". Responses to knowledge questions were categorized into correct and wrong

responses, while responses to perception questions were organized into similar categories

(e.g., "strongly agree" and "agree" were taken to be one category).

Univariate logistic regression analysis was used to determine demographics, vaccine

knowledge and vaccine safety perceptions factors associated with vaccine acceptance in

pregnant and lactating women separately. Factors most strongly associated with vaccine

acceptance in the univariate analyses were entered sequentially into a multivariable forward

stepwise regression analysis with significance levels to enter/stay of 0.10/0.05. Model

goodness-of-fit was also assessed using the Akaike information criterion (AIC). All data was

analyzed using SPSS version 19.0 (IBM Corp, Armonk, USA). The Checklist for Reporting

Results of Internet E-Surveys (CHERRIES) was used in the reporting of this study. (19)

Results

A total of 201 pregnant women and 207 lactating women participated in the survey (**Table I**).

Majority of the respondents in both pregnant and lactating groups were 21-34 years old (77.6%

and 66.7% respectively), Singaporean citizens (79.1% and 73.9%), of Chinese ethnicity (48.3%)

and 52.7%) and without pre-existing medical conditions (97% and 92.7%)

Pregnant women

The majority of pregnant women were aware of the mRNA vaccine's mode of action (69.6%),

however only 32.9% of pregnant women reported to be aware that the vaccine was

efficacious in reducing risk of COVID-19 in pregnant women (Table II). Only 61/201

(30.3%) were agreeable to take the COVID-19 vaccine if it was offered to them, while the

remainder were unsure (n=91, 45.3%) or unwilling (n=49, 24.4%). Of those who were unsure

or unwilling to take the vaccine 92.9% (109/140) had doubts about the safety of the vaccine,

78.6% (110/140) were concerned about the side effects they would experience from the

vaccine and 92.1% (129/140) were worried about the unknown short and long-term effects of

the vaccine on the pregnancy and unborn child. Most in this group reported that they would

take the vaccine only if there was more data available on its safety during pregnancy

(119/140, 70.0%).

Regression analysis demonstrated that factors associated with vaccine acceptance in pregnant

women were a lower monthly household income, appropriate knowledge regarding vaccine

mechanism, higher maternal perceived risk of COVID-19, and perceived general safety of the

vaccine during pregnancy (**Table III**).

<u>Lactating women</u>

Up to 61.7% of lactating women were aware of the vaccine mode of action, and 72.9% were

aware of its efficacy in reducing COVID-19 risk (**Table IV**). Among lactating women, 35

(16.9%) were agreeable to take the vaccine, while 129 (62.3%) were unsure, and 43 (20.8%)

were unwilling.

Among lactating women who were unsure or unwilling to take the vaccine (n= 172), many

were worried about the side effects that they would experience (147/172, 85.5%), that the

virus would be transmitted via breastmilk to the infant (105/172, 61.6%) and anxious about

the potential negative long-term effects of the vaccine on the breastfeeding child (130/172,

75.6%). Lactating women also reported to be willing to take the vaccine only if more data on

its safety in breastfeeding was available (144/172, 83.7%).

Regression analysis demonstrated that those who received primary school level education

were more willing to accept the vaccine than those who had at least an undergraduate degree.

Vaccine acceptance was also greater in those with appropriate knowledge regarding vaccine

mechanism of action, high maternal perceived risk of COVID-19 and low perceived long-

term negative effects on the breastfeeding child (**Table V**).

Discussion

We sought to determine factors associated with COVID-19 vaccine acceptance among

pregnant and lactating women in Singapore to guide vaccination efforts in these vulnerable

populations. From this survey, we found low vaccine acceptance, varying levels of

understanding of vaccine efficacy, and high proportions of safety concerns regarding possible

side-effects on the unborn or breastfeeding child in our local population.

Reported rates of COVID-19 vaccine acceptance in pregnant women vary worldwide, from

77% in a study conducted in China to 37% in a study conducted in Turkey. (20,21) Vaccine

acceptance in our population appears to be low at 30%, suggesting the need for an action plan

to improve acceptance to achieve adequate vaccination rates in this population. Our low

vaccine acceptance appears to be guided by a low perceived risk of infection due to low

national infection rates, as perceived high COVID-19 infection risk was significantly associated with greater vaccine acceptance in both pregnant and lactating women in our study. The low vaccine acceptance in the survey population may have also been affected by recommendations by the local Health Ministry at the time of the survey. Pregnant women were advised against taking the COVID-19 vaccine, while lactating mothers were discouraged from breastfeeding for 5 to 7 days after vaccination. In the United States of America, where organizations support vaccination of pregnant and lactating women, vaccine acceptance appeared to be higher than in our population (44-58% and 55% in pregnant and lactating women respectively). Although current recommendations in Singapore have been revised to encourage vaccinations in pregnant and lactating women as on 31st May 2021, it is uncertain whether this will increase vaccine acceptance.

Surprisingly, a larger proportion of pregnant women were agreeable for the vaccine compared to lactating mothers. This was contrary to other studies that reported lower mRNA vaccine acceptance in pregnant compared to non-pregnant or lactating women, which reported concerns regarding potential unknown long-term consequences in the developing fetus among pregnant women. A possible explanation is that pregnant women may have been informed of the greater risk for severe disease in infected pregnant women, thus increasing their vaccine acceptance. Pregnant women are also more likely to have had contact with their healthcare providers compared with lactating women, which could have helped to alleviate their concerns and doubts regarding vaccine safety. Nevertheless, this demonstrates that the concerns of both lactating and pregnant women need to be addressed to increase their vaccine acceptance.

Several studies have reported safety concerns of mothers about their child or their own health as the primary reason for low vaccine acceptance amongst pregnant and lactating women. (16,21,22) Similarly, the lack of safety data of the COVID-19 vaccine was a significant

factor affecting vaccine acceptability in our population. Pregnant women were concerned

about general safety of the vaccine during pregnancy, while lactating mothers were

concerned about the possible long-term side effects that the vaccine could have on their child.

This is unsurprising, as both pregnant and lactating women were excluded from the initial

mRNA-based vaccine trials, limiting the available data on safety and efficacy in these groups.

However, since then, observational data from other countries has shown that the mRNA-

based vaccine is safe in pregnant and lactating women without any discernible short or

medium-term side-effects to the fetus or child. (23-25) Dissemination of this safety and efficacy

data in a timely manner is in the key to increasing vaccine uptake in these populations.

While the majority of pregnant women and mothers were aware of the mechanism of action

of the mRNA-based vaccines, approximately a third were unsure or unaware of this. Lack of

knowledge regarding vaccine mechanism of action was associated with poor vaccine

acceptance in both pregnant and lactating women, indicating the potential for educating

women on the vaccine's mechanism of action, so as to increase vaccine acceptance rates. At

the time of this survey, only mRNA vaccines were available for vaccination in Singapore.

However, as other types of vaccines become available in the future, adequate public

education regarding the different mechanism of actions of each vaccine may become

important.

We found that lower monthly household income and lower education level were associated

with higher vaccine acceptance in pregnant and lactating mothers respectively. This is

contrary to other studies where higher education level and socioeconomic status were

associated with greater vaccine acceptance. (26, 27) A possible explanation for this is that

women who were better educated and of higher socioeconomic status were better informed

about the lack of safety data on the vaccine. This may also explain our finding of higher

vaccine acceptance in pregnant compared to lactating women, as a smaller proportion of

pregnant women had an undergraduate degree or higher (44.3% vs. 65.7%). Indeed, we found

that majority of both pregnant and lactating women expressed willingness to take the vaccine

when more safety data became available.

A limitation of our study is the cross-sectional nature and the short study period of 3 months.

Since conducting our survey, government recommendations regarding vaccination in these

groups of women have evolved, with an emphasis that it is safe and recommended. As such,

perceptions of pregnant and lactating women may have also changed. However, we believe

that our results are still valid in informing educational strategies in women who are unsure or

unwilling to take the vaccine despite changes in recommendations. In addition, we measured

vaccine acceptance via participant report, and not actual vaccination rates. Reported intent

may not translate into actual behavior on vaccination, (28) and whether addressing safety

concerns would be adequate in increasing vaccine uptake remains to be determined.

To our knowledge, this is the first survey on COVID-19 vaccine perceptions in pregnant and

lactating women in Singapore. Our study is timely in informing education programs and

vaccination efforts in these groups to design a targeted action plan. Based on our results, an

educational brochure is currently being prepared to better inform pregnant women about

COVID-19 vaccination. We also propose the use of other platforms such as mass media and

social media to help raise awareness and knowledge to aid improve the acceptance of the

COVID-19 vaccine. With the expansion of the local vaccination program to pregnant and

lactating women, it is important for educational messages to be individualized such that

concerns regarding safety and efficacy are adequately addressed.

Conclusion

COVID-19 vaccine acceptance in pregnant and lactating women in Singapore is generally

low. Factors affecting low vaccine acceptability among both pregnant and lactating women

include a low perceived infection risk, and concerns of unknown safety for the mother and child. Addressing safety concerns and infection risk may help improve COVID-19 vaccine acceptance in pregnant and lactating women in Singapore.

References

- Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384:403-16.
- Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid 19 Vaccine. N Engl J Med 2020; 383:2603-15.
- Ministry of Health, Singapore. Expert committee on COVID-19 vaccination endorses use
 of Pfizer-BioNTech COVID-19 Vaccine Singapore 2021. Available at:
 www.moh.gov.sg/news-highlights/details/expert-committee-on-covid-19-vaccination-endorses-use-of-pfizer-biontech-covid-19-vaccine. Accessed Jun 12, 2021.
- Ministry of Health, Singapore. Frequently Asked Questions (FAQs) on COVID-19
 Vaccination [Online]. 2021. Available at: www.moh.gov.sg/covid-19/vaccination/faqs.

 Accessed Feburary 1, 2021.
- Rasmussen SA, Jamieson DJ. Pregnancy, Postpartum Care, and COVID-19 Vaccination in 2021. JAMA 2021; 325:1099-100.
- 6. The American College of Obstetrics and Gynaecology (ACOG). Vaccinating Pregnant and Lactating Patients Against COVID-19- Practice advisory, 2020 [Online]. Available at: www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19. Accessed June 8, 2021.
- World Health Organization. COVID-19 clinical management: living guidance, 25 January 2021. [Online]. Available at: apps.who.int/iris/handle/10665/338882. Accessed June 7, 2021.
- 8. Academy of Breastfeeding Medicine. Considerations for COVID-19 Vaccination in Lactation Policy statement [Online]. Available at: www.bfmed.org/abm-statement-considerations-for-covid-19-vaccination-in-lactation. Accessed June 6, 2021.

- Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and
 mortality in COVID-19: A global systematic review and meta-analysis. PLoS One [online]
 2021; 16:e0247461. Available at:
 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247461. Accessed
 June 1, 2021.
- 10. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ [online] 2020; 370:m3320. Available at: https://www.bmj.com/content/370/bmj.m3320. Accessed June 5, 2021
- 11. Zambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status United States, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1641-7
- 12. Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ 2021; 193:E540-8.
- 13. Goh XL, Low YF, Ng CH, Amin Z, Ng YPM. Incidence of SARS-CoV-2 vertical transmission: a meta-analysis. Arch Dis Child Fetal Neonatal Ed 2021; 106:112-3.
- 14. Mattar CN, Kalimuddin S, Sadarangani SP, et al. Pregnancy Outcomes in COVID-19: A Prospective Cohort Study in Singapore. Ann Acad Med Singap 2020; 49:857-69.
- 15. Skjefte M, Ngirbabul M, Akeju O, et al. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries. Eur J Epidemiol 2021; 36:197-211.
- 16. Sutton D, D'Alton M, Zhang Y, et al. COVID-19 Vaccine Acceptance Among Pregnant, Breastfeeding and Non-pregnant Reproductive Aged Women. Am J Obstet Gynecol [online] MFM 2021; 100403. Available at:

- https://www.sciencedirect.com/science/article/pii/S2589933321000987?via%3Dihub. Accessed June 2, 2021
- 17. Mannan KA, Farhana KM. Knowledge, Attitude and Acceptance of a COVID-19 Vaccine: A Global Cross-Sectional Study. International Research Journal of Business and Social Science. 2020; 6:1-23
- 18. Lin Y, Hu Z, Zhao Q, et al. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl Trop Dis [online] 2020; 14:e0008961.Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775119/. Accessed June 2, 2021.
- 19. Eysenbach G. Improving the quality of Web surveys: the Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J Med Internet Res 2004; 6:e34-e.
- 20. Tao L, Wang R, Han N, et al. Acceptance of a COVID-19 vaccine and associated factors among pregnant women in China: a multi-center cross-sectional study based on health belief model. Hum Vaccin & Immunother [online] 2021; 1-10. Available at: https://www.tandfonline.com/doi/abs/10.1080/21645515.2021.1892432?journalCode=kh vi20. Accessed at June 2, 2021.
- 21. Goncu Ayhan S, Oluklu D, Atalay A, et al. COVID-19 vaccine acceptance in pregnant women. Int J Gynecol Obstet [online] 2021; 10.1002/ijgo.13713. Available at: https://obgyn.onlinelibrary.wiley.com/doi/epdf/10.1002/ijgo.13713. Accessed June 2, 2021.
- 22. Levy AT, Singh S, Riley LE, Prabhu M. Acceptance of COVID-19 vaccination in pregnancy: A survey study. Am J Obstet Gynecol MFM [online] 2021; 100399.

 Available at: https://www.sciencedirect.com/science/article/pii/S258993332100094X?via%3Dihub.

Accessed June 2, 2021.

- 23. Shanes ED, Otero S, Mithal LB, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Pregnancy: Measures of Immunity and Placental Histopathology. Obstet Gynecol [online] 2021; 10.1097/AOG.000000000000004457. Available at: https://journals.lww.com/greenjournal/Fulltext/9900/Severe_Acute_Respiratory_Syndrome_Coronavirus_2.206.aspx. Accessed June 2, 2021
- 24. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol [online] 2021; S0002-9378(21)00187-3. Available at: https://www.sciencedirect.com/science/article/pii/S0002937821001873?via%3Dihub. Accessed June 2, 2021
- 25. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. N Engl J Med 2021; 384:2273-2282.
- 26. Gadoth A, Halbrook M, Martin-Blais R, et al. Cross-sectional Assessment of COVID-19 Vaccine Acceptance Among Health Care Workers in Los Angeles. Ann Intern Med 2021; 174:882-885.
- 27. Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 2021; 27:225-8.
- 28. Sheeran P. Intention—behavior relations: a conceptual and empirical review. Eur Rev Soc Psychol 2002; 12:1-36.

Table I. Participant characteristics of pregnant and lactating women

Demographics	Pregnant	Lactating
	(n=201)	(n=207)
Age group, years, n (%)		
21-34	156 (77.6)	138 (66.7)
35 and above	45 (22.4)	69 (33.3)
Nationality, n (%)		
Singapore citizen	159 (79.1)	153 (73.9)
Singapore Permanent Resident	41 (20.4)	26 (12.6)
Non-resident	1 (0.5)	28 (13.5)
Ethnicity, n (%)		
Chinese	97 (48.3)	109 (52.7)
Malay	77 (38.3)	49 (23.7)
Indian	14 (7.0)	21 (10.1)
Others	13 (6.5)	28 (13.5)
Marital status, n (%)		
Single	7 (3.5)	3 (1.4)
Married	192 (95.5)	203 (98.1)
Divorced/Separated	2 (1)	1 (0.5)

Highest Education level, n (%)		
No formal education/Primary level	9 (4.5)	4 (2.9)
Secondary or post-secondary level	103 (51.2)	65 (31.4)
Undergraduate/Postgraduate	89 (44.3)	136 (65.7)
Employment Status, n (%)		
Self-employed	13 (6.5)	12 (5.8)
Employed for wages	148 (73.6)	156 (75.4)
Unemployed	40 (19.9)	39 (18.8)
Average Monthly Household Income, n (%)		
≤ SGD 5,000	83 (41.3)	52 (25.1)
SGD 5,001 – 10,000	50 (24.9)	67 (32.4)
SGD 10,001 – 15,000	24 (11.9)	33 (15.9)
SGD 15,001 – 30,000	23 (11.4)	32 (15.5)
≥ SGD 30,001	21 (10.4)	23 (11.1)
Parity, n (%)		
Primiparous	0	92 (44.4)
Multiparous	201 (100.0)	116 (55.6)
Age of youngest infant		
<1 month		120 (58.0)
1 to <3 months	N.A.	26 (12.6)
3 to <6 months		15 (7.2)
6 to <12 months		21 (10.1)
12 months or older		25 (12.1)

Pre-existing medical condition		
No	195 (97.0)	192 (92.8)
Yes	4 (2.0)	15 (7.2)
SGD, Singapore dollar		

Table II. Survey responses for pregnant women

		Total	Accept	Unsure or
		(n=201)	vaccine	decline
Questions	Responses		(n=61)	vaccine
				(n=140)
Health status				
Have you had previous	Yes	4 (2.0)	1 (1.6)	3 (2.1)
experience with COVID-19 (e.g.,	No	197 (98.0)	60 (98.4)	137 (97.9)
infection in self/family				
member/friend/work-related				
contact				
How do you rate your current	Good or very good	170 (85.5)	54 (88.5)	116 (82.8)
overall health status?	Fair	31 (15.4)	7 (11.5)	24 (17.1)
	Poor or very poor	0 (0.0)	0	0
Knowledge				
The vaccine works by training the	Agree or strongly	124 (61.7)	58 (95.1)	66 (47.1)
body's immune system to	agree			
produce antibodies against	Unsure	71 (35.3)	3 (4.9)	68 (48.6)
COVID-19 faster in case of a real	Disagree or strongly	6 (3.0)	0 (0)	6 (4.3)
infection	disagree		()	,
How effective do you think the	Very or some what	66 (32.9)	37 (60.7)	29 (20.7)
COVID-19 vaccination is in	effective	(-2.5)	(55.7)	(-0.1)
preventing pregnant women from	Unsure	123 (61.2)	24 (39.3)	99 (70.7)
getting infected with the virus?	Not too effective or	12 (6.0)	0 (0)	12 (8.6)
getting infected with the virus:	not effective at all	12 (0.0)	0 (0)	12 (0.0)
Daycontions	not effective at all			
Perceptions COMP 10	***	22 (11 7)	14 (02.0)	0 (5.1)
My risk of contracting COVID-19 is	High or very high	23 (11.5)	14 (23.0)	9 (6.4)

	Neutral	121 (60.2)	27 (60.7)	84 (60.0)
	Low or very low	57 (28.4)	10 (16.4)	47 (33.6)
How worried are you about	Concerned or very	128 (63.1)	42 (68.9)	86 (61.4)
contracting COVID-19?	concerned			
	Neutral	62 (30.8)	17 (27.9)	45 (32.1)
	Not concerned or not	11 (5.5)	2 (3.3)	9 (6.4)
	concerned at all			
I will only take the vaccine when	Agree or strongly	170 (84.6)	51 (83.6)	119 (85.0)
more data about safety in	agree			
pregnancy is available	Unsure	24 (11.9)	8 (13.1)	16 (11.4)
	Disagree or strongly	7 (3.5)	2 (3.3)	5 (3.6)
	disagree			
If a pregnant woman gets	Very to somewhat	127 (63.1)	44 (72.1)	83 (59.3)
COVID-19, how likely will the	likely			
virus harm, her pregnancy and	Unsure	62 (30.8)	13 (21.3)	49 (35.0)
her unborn child?	Very to somewhat	12 (6.0)	4 (6.6)	8 (5.7)
	unlikely			
How safe do you think the	Completely to	36 (17.9)	26 (42.6)	10 (7.1)
COVID-19 vaccinations are for	somewhat safe			
pregnant women?	Unsure	133 (66.2)	34 (55.7)	99 (10.7)
	Completely or	32 (15.9)	1 (1.6)	31 (22.1)
	somewhat unsafe			
I am concerned that I can	Agree or strongly	84 (41.8)	29 (47.5)	55 (39.3)
transmit the virus to people	agree			
around me if I take the vaccine	Unsure	69 (34.3)	17 (27.9)	52 (37.1)
	Disagree or strongly	48 (23.9)	15 (24.6)	33 (23.6)
	disagree			

I am concerned about the side	Agree or strongly	158 (78.6)	48 (78.7)	110 (78.6)
effects I may experience post	agree			
vaccination (pain, swelling,	Unsure	17 (8.5)	5 (8.2)	12 (8.6)
headache, body ache, fever,	Disagree or strongly	26 (12.9)	8 (13.1)	18 (12.9)
allergic reaction)	disagree			
I am worried about the unknown	Agree or strongly	181 (90.1)	52 (85.2)	129 (92.1)
short and long term effects of the	agree			
COVID-19 vaccine on my	Unsure	18 (9.0)	8 (13.1)	10 (7.1)
pregnancy and my unborn baby.	Disagree or strongly	2 (1.0)	1 (1.6)	1 (0.7)
	disagree			_

Table III. Multivariate regression analysis for vaccine acceptance in pregnant women

Factors	Univariate Odds ratio (95% confidence interval)	p
Monthly household income, SGD	,	
5000 below	Ref	N.A.
5001 to 15000	0.39 (0.16, 0.94)	0.04
Above 15000	0.23 (0.07, 0.78)	0.02
Knowledge about mechanism of action		
Unsure/Disagree or strongly disagree	Ref	N.A.
Agree or strongly agree	18.52 (5.05, 68.00)	< 0.001
Maternal perceived risk of COVID		
Low or very low	Ref	N.A.
Neutral	2.98 (1.13, 7.86)	0.03
High or very high	6.25 (1.59, 24.56)	0.009
Perceived general safety of vaccine		
Somewhat or completely unsafe	Ref	N.A.
Unsure	5.23 (0.61, 44.96)	0.13
Somewhat or completely safe	38.55 (3.93, 377.82)	0.002

SGD, Singapore dollar.

Table IV. Survey responses for lactating women

		Total	Accept	Unsure or
0 4		(n=207)	vaccine	decline
Questions	Responses		(n=61)	vaccine
				(n=140)
Health status				
Have you had previous	Yes	13 (6.3)	6 (17.1)	7 (4.1)
experience with COVID-19	No	194 (93.7)	29 (82.9)	165 (95.9)
_	NO	194 (93.7)	29 (62.9)	103 (93.9)
(e.g., infection in self/family				
member/friend/work-related				
contact				
How do you rate your current	Good or very good	177 (85.5)	34 (97.1)	143 (83.1)
overall health status?	Fair	29 (14.0)	1 (2.9)	28 (16.3)
	Poor or very poor	1 (0.5)	0 (0)	1 (0.6)
Knowledge				
The vaccine is currently	Agree or strongly	69 (33.3)	26 (74.3)	43 (25.0)
recommended to breastfeeding	agree	, ,	, ,	, ,
_		07 (46 0)	6 (17.1)	01 (52 0)
mothers	Unsure	97 (46.9)	6 (17.1)	91 (52.9)
	Disagree or strongly	41 (19.8)	3 (8.6)	38 (22.1)
	disagree			
The vaccine works by training	Agree or strongly	144 (69.6)	34 (97.1)	110 (64.0)
the body's immune system to	agree			
produce antibodies against	Unsure	57 (27.5)	1 (2.9)	56 (32.6)
COVID-19 faster in case of a	Disagree or strongly	6 (2.9)	0 (0)	6 (3.5)
real infection	disagree			
Taking the vaccine reduces my	Agree or strongly	151 (72.9)	31 (88.6)	120 (69.8)
chances of getting COVID-19		(. -)	2 - (30.0)	(0).0)
chances of getting COVID-19	agree			

	Unsure	40 (19.3)	3 (8.6)	37 (21.5)
	Disagree or strongly	16 (7.7)	1 (2.9)	15 (8.7)
	disagree			
Perceptions				
My risk of contracting COVID- 19 is	High or very high	28 (13.5)	14 (40.0)	14 (8.1)
19 18	Neutral	110 (53.1)	10 (28.6)	100 (58.1)
	Low or very low	69 (33.3)	11 (31.4)	58 (33.7)
How worried are you about	Concerned or very	138 (77.3)	25 (71.4)	113 (65.7)
contracting COVID-19?	concerned			
	Neutral	19 (9.2)	5 (14.3)	49 (28.5)
	Not concerned or not	28 (13.5)	5 (14.3)	10 (5.8)
	concerned at all			
I will only take the vaccine	Agree or strongly	160 (77.3)	16 (45.7)	144 (83.7)
when more data about safety in	agree			
breastfeeding is available	Unsure	19 (9.2)	3 (8.6)	16 (9.3)
	Disagree or strongly	28 (13.5)	16 (45.7)	12 (7.0)
	disagree			
I am willing to pay for the	Yes	105 (50.7)	11 (31.4)	91 (52.9)
vaccine if needed	No	102 (49.3)	24 (68.6)	81 (47.1)
I am concerned about the side	Agree or strongly	170 (82.1)	23 (65.7)	147 (85.6)
effects I may experience post	agree			
vaccination (pain, swelling,	Unsure	20 (9.7)	4 (11.4)	16 (9.3)
headache, body ache, fever,	Disagree or strongly	17 (8.2)	8 (22.9)	9 (5.2)
allergic reaction)	disagree			
I am concerned that I can	Agree or strongly	76 (36.7)	12 (34.3)	64 (37.2)
transmit the virus to people	agree			
around me if I take the vaccine	Unsure	49 (23.7)	2 (5.7)	47 (27.3)

	Disagree or strongly	82 (39.6)	21 (60.0)	61 (35.5)
	disagree			
I am concerned that the virus	Agree or strongly	117 (56.5)	11 (31.4)	106 (61.6)
can be transmitted via milk to	agree			
my breastfeeding infant if I	Unsure	49 (23.7)	7 (20.0)	42 (24.4)
take the vaccine	Disagree or strongly	41 (19.8)	17 (48.6)	24 (14.0)
	disagree			
I am worried that the COVID-	Agree or strongly	144 (69.6)	13 (40.0)	130 (75.6)
19 vaccine can have long-term	agree			
effects on my breastfeeding	Unsure	44 (21.3)	8 (20.9)	8 (22.9)
infant	Disagree or strongly	19 (9.2)	13 (37.1)	6 (3.5)
	disagree			
I will temporarily stop	Agree or strongly	72 (34.8)	10 (28.6)	62 (36.0)
breastfeeding for 5-7 days	agree			
following vaccination.	Unsure	69 (33.3)	8 (22.9)	61 (35.5)
	Disagree or strongly	66 (31.9)	17 (48.6)	17 (48.6)
	disagree			
I believe that taking the vaccine	Agree or strongly	79 (38.2)	26 (74.3)	53 (30.8)
will protect my baby from the	agree			
virus when I resume	Unsure	112 (54.1)	7 (20.0)	105 (61.0)
breastfeeding after vaccination.	Disagree or strongly	16 (7.7)	2 (5.7)	14 (8.1)
	disagree			

Table V. Multivariate regression analysis for vaccine acceptance in lactating women

Factors	Univariate Odds ratio (95% confidence interval)	p
Highest Education level		
No formal education/Primary	Ref	N.A.
Secondary/post-secondary	0.04 (0.01, 0.48)	0.10
Undergraduate or above	0.10 (0.01, 0.90)	0.04
Knowledge about mechanism of action		
Unsure/Disagree or strongly disagree	Ref	N.A.
Agree or strongly agree	9.44 (1.10, 81.0)	0.04
Maternal perceived risk of COVID		
Low or very low	Ref	N.A.
Neutral	0.68 (0.22, 2.06)	0.49
High or very high	9.10 (2.40, 34.47)	0.001
Perceived long-term negative effects on		
breastfeeding child		
Disagree or strongly disagree	Ref	N.A.
Unsure	0.15 (0.03, 0.33)	0.01
Agree or strongly agree	0.08 (0.02, 0.31)	< 0.001
Perceived long-term protection of baby		
Disagree or strongly disagree	Ref	N.A.
Unsure	0.17 (0.02, 1.42)	0.10
Agree or strongly agree	0.68 (0.09, 5.01)	0.71